These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36868570)

  • 1. Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.
    Frias A; Di Leo L; Antoranz A; Nazerai L; Carretta M; Bodemeyer V; Pagliuca C; Dahl C; Claps G; Mandelli GE; Andhari MD; Pacheco MP; Sauter T; Robert C; Guldberg P; Madsen DH; Cecconi F; Bosisio FM; De Zio D
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Ambra1 promotes melanoma growth and invasion.
    Di Leo L; Bodemeyer V; Bosisio FM; Claps G; Carretta M; Rizza S; Faienza F; Frias A; Khan S; Bordi M; Pacheco MP; Di Martino J; Bravo-Cordero JJ; Daniel CJ; Sears RC; Donia M; Madsen DH; Guldberg P; Filomeni G; Sauter T; Robert C; De Zio D; Cecconi F
    Nat Commun; 2021 May; 12(1):2550. PubMed ID: 33953176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMBRA1 and FAK1: crosstalking for improved targeted therapy in melanoma.
    Di Leo L; De Zio D
    Mol Cell Oncol; 2021; 8(4):1949955. PubMed ID: 34616874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
    Khalili JS; Liu S; Rodríguez-Cruz TG; Whittington M; Wardell S; Liu C; Zhang M; Cooper ZA; Frederick DT; Li Y; Zhang M; Joseph RW; Bernatchez C; Ekmekcioglu S; Grimm E; Radvanyi LG; Davis RE; Davies MA; Wargo JA; Hwu P; Lizée G
    Clin Cancer Res; 2012 Oct; 18(19):5329-40. PubMed ID: 22850568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMBRA1 has an impact on melanoma development beyond autophagy.
    Di Leo L; De Zio D
    Autophagy; 2021 Jul; 17(7):1802-1803. PubMed ID: 34156327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
    Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE
    Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
    Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
    Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global pannexin 1 deletion increases tumor-infiltrating lymphocytes in the BRAF/Pten mouse melanoma model.
    Sanchez-Pupo RE; Finch GA; Johnston DE; Craig H; Abdo R; Barr K; Kerfoot S; Dagnino L; Penuela S
    Mol Oncol; 2024 Apr; 18(4):969-987. PubMed ID: 38327091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status.
    Chen L; Wen Y; Xiong J; Chen Y; Chen CB
    Biomed Res Int; 2023; 2023():1189022. PubMed ID: 36704723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E-dependent role of autophagy in uveal melanoma.
    Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
    Armstrong JL; Hill DS; McKee CS; Hernandez-Tiedra S; Lorente M; Lopez-Valero I; Eleni Anagnostou M; Babatunde F; Corazzari M; Redfern CPF; Velasco G; Lovat PE
    J Invest Dermatol; 2015 Jun; 135(6):1629-1637. PubMed ID: 25674907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
    Jang GH; Lee M
    Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
    Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
    Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
    Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
    Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
    J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.